

APPLE 2025

The 15th Asia-Pacific Primary Liver Cancer Expert Meeting

■ Date

July 11 (Fri.) – 13 (Sun.), 2025

■ Venue

Kobe Portopia Hotel

■ Hosting Chairperson


Takumi Fukumoto

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery,
Kobe University Graduate School of Medicine

<https://www.c-linkage.co.jp/apple2025/>



PROGRAM BOOK



One**Liver**

Together, let's stop
chronic liver disease
and one day cure HCC

CONTENTS

INTRODUCTION

Welcome Message 2

Organizing Committee 3

GENERAL INFORMATION

General Information 4

Conference Floor Map 11

FACULTY

Faculty List 12

PROGRAM AT A GLANCE

Friday, July 11, 2025 14

Saturday, July 12, 2025 15

Sunday, July 13, 2025 16

AGENDA

Saturday, July 12, 2025 17

Sunday, July 13, 2025 21

Acknowledgment of Sponsors 34

WELCOME MESSAGE

Dear Colleagues and Friends,

It is with great pleasure that I invite you to join us for the Asia-Pacific Primary Liver Cancer Expert (APPLE) Conference 2025, which will be held from July 11th to 13th at the Portopia Hotel in Kobe, Japan. This year marks the first time in six years that the APPLE Conference will return to Japan. APPLE 2025 will take place following the 61st Annual Meeting of Japan Liver Cancer Association.

The theme for APPLE 2025 is "A New Era in Multidisciplinary Treatment for Liver Cancer." A number of new molecular-targeted agents and combined immunotherapies are now available to treat liver cancer, leading to significantly improved prognoses. Additionally, new technologies, such as particle therapy and robot-assisted surgery, have become available for the local treatment of liver cancer. The emergence of these drugs and treatment modalities has dramatically transformed the landscape of multidisciplinary liver cancer treatment. To reflect these advancements, we have designed a comprehensive program that will cover the latest developments in liver cancer research. We expect that it will bring together experts from various fields to share their knowledge and expertise. Our goal is to foster collaboration and innovation, ultimately improving patient outcomes.

Kobe, our host city, is a vibrant and beautiful port city known for its scenic harbor views, exquisite cuisine, and warm hospitality. From the historic Kitano district to the stunning views from Mount Rokko, Kobe offers a rich cultural experience that we hope you will enjoy. We also encourage you to take advantage of the opportunity to visit the Osaka Expo 2025, which will be taking place in the city adjacent to Kobe. This global event offers a unique chance to experience cutting-edge technology and culture from around the world.

We look forward to welcoming you to Kobe for APPLE 2025 and are excited about the meaningful discussions and collaborations that will occur. Together, let us advance the field of liver cancer and make a lasting impact on our patients' lives.

Sincerely,



Takumi Fukumoto

Professor, Department of Surgery,
Hepato-Biliary-Pancreatic Surgery Division,
Kobe University Graduate School of Medicine, Japan

ORGANIZING COMMITTEE

Governing Board of the APPLE Association

President

Jian Zhou (Shanghai)

Secretary General

Do Young Kim (Seoul)

Vice-Secretary General

Ying-Hong Shi (Shanghai)

Treasurer

Chih-Hung Hsu (Taipei)

Scientific Committee Chairs

Ghassan Abou-Alfa (New York)

Masafumi Ikeda (Kashiwa)

Publication Chairs

Masayuki Kurosaki (Tokyo)

Young Nyun Park (Seoul)

Education Committee Chairs

Pierce Chow (Singapore)

Chiun Hsu (Taipei)

Advisory Board Members

Ann-Lii Cheng (Taipei)

Kwang-Hyub Han (Seoul)

Norihiro Kokudo (Tokyo)

Masatoshi Kudo (Osaka)

Jinsil Seong (Seoul)

Sheng-Long Ye (Shanghai)

Council

Tan To Cheung (Hong Kong)

Jong Young Choi (Gwangmyeong)

Kiyoshi Hasegawa (Tokyo)

Naomi Khaing Than Hlaing (Yangon)

Yi-Hsiang Huang (Taipei)

Yoon Jun Kim (Seoul)

Ming Kuang (Guangzhou)

Hyunchul Rhim (Seoul)

Ryosuke Tateishi (Tokyo)

Linda Wong (Honolulu)

Kengo Yoshimitsu (Fukuoka)

Zhao-Chong Zeng (Shanghai)

Andrew Zhu (Shanghai)

GENERAL INFORMATION

- **The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2025)**
- **Theme:** "A New Era in Multidisciplinary Treatment for Liver Cancer"
- **Date:** July 11 (Fri) – 13 (Sun), 2025
- **Venue:** Kobe Portopia Hotel
6-10-1 Minatojima-nakamachi, Chuo-ku, Kobe, Hyogo 650-0046, Japan
- **Official Language:** English
- **Hosted by:** The Organizing Committee of APPLE 2025
The Asia-Pacific Primary Liver Cancer Expert Association
- **Hosting Chairperson:**
Takumi Fukumoto (Professor, Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine)
- **Co-Hosting Chairpersons:**
Michiie Sakamoto (Dean, Professor, School of Medicine, International University of Health and Welfare)
Masafumi Ikeda (Chief, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)
- **Congress Secretariat:** c/o Convention Linkage, Inc.
PIAS TOWER 11F, 3-19-3 Toyosaki, Kita-ku, Osaka 531-0072, Japan
Tel: +81-6-6377-2188 Fax: +81-6-6377-2075
E-mail: apple2025@c-linkage.co.jp

1 Conference Schedule and Event Highlights

◆ Opening Ceremony

- **Location:**
Room A "Kairaku 1+2," Main Building B1F
- **Date & Time:** July 12, 8:30–8:40

◆ Closing Ceremony

- **Location:**
Room A "Kairaku 1+2," Main Building B1F
- **Date & Time:** July 13, 16:30–16:40

◆ Breakfast Symposium and Luncheon Symposium

- Breakfast sandwiches and boxed lunches are served at each seminar.
- The fee for these meals is included in the conference registration fee.

◆ Coffee Breaks

- **Location:** "Waraku," Main Building B1F
- **Opening Hours:**
 - July 12, 10:30–10:45 / 15:50–16:00
 - July 13, 10:00–10:15 / 15:15–15:30

◆ Gala Dinner

- **Location:** Banquet Hall "Ohwada," South Wing 1F, Kobe Portopia Hotel
- **Date & Time:** July 12, 19:00–21:00
- The fee for these meals is included in the conference registration fee.

◆ General Assembly

- **Location:** Banquet Hall "Ohwada," South Wing 1F, Kobe Portopia Hotel
- **Date & Time:**
July 12, 19:00–19:20 (during the Gala Dinner)

◆ Corporate Exhibitions

Location: "Waraku," Main Building B1F

Opening Hours:

- July 11, 9:00–16:00
- July 12, 9:00–18:00
- July 13, 8:00–15:30

- A refreshment corner with free drinks is provided in "Waraku," the Exhibition Hall.

2 Participant Guidelines

1. Online Registration for Participation

The conference will be held on-site only.

Online registration is mandatory to attend this conference.

Please review the registration guidelines below before proceeding.



◆ Online Registration Period

Thursday, May 1, 2025 – Sunday, July 13, 2025

* A reception desk will be available on the day of the conference; however, we will not accept cash payments on-site. All registrations must be completed online. We recommend registering in advance to avoid potential delays at the reception desk.

◆ Registration Fees

Registration Category	
Doctor, Healthcare Professional	45,000 yen
Fellow, Resident, Researcher, Other	40,000 yen
Poster Presenter*	30,000 yen
Healthcare Industry Professional	75,000 yen
Guest**	20,000 yen
APPLE Academy	
Doctor, Healthcare Professional, Fellow, Resident, Researcher	3,000 yen
Other	5,000 yen

* The fee applies to Poster Presenters who will be presenting exclusively at APPLE 2025.

** Please note that "GUEST" registration is intended for accompanying persons—such as a spouse, partner, or close family member.

This registration type provides access to select non-conference activities, including designated social events and exhibition areas, if applicable.

However, it does not include:

- Admission to scientific or official conference sessions
- Access to conference materials, certificates, or academic credits

Registration for APPLE ACADEMY will be available via your My Page after you have completed your registration for APPLE 2025.

◆ Payment Information

Payment Method: Credit card only (Visa, MasterCard, JCB, AMEX, Diners Club)

◆ Cancellation / Refund Policy

No refunds will be issued for cancellations once registration is complete, regardless of the reason.

◆ Receipt

Upon completing your registration, you will receive a "Registration Completion Email". This email will contain a link to download your receipt.

2. How to Participate

2-1. For All Participants

Upon arrival, all participants — including invited faculty members* and general registrants — should present their "Registration Confirmation" QR code (to be downloaded from their My Page) at the Registration Desk to receive their name badge.

* The congress secretariat will inform the invited faculty members individually regarding their My Page.

Please print the "Registration Confirmation" QR code and have it with you, or save the QR code image on your mobile phone for onsite ticketing. When you present the QR code at the ticketing terminal at the Registration Desk at the venue, your Name Badge will be issued based on the information you provided.

Attention: Name badges must be worn at all times during the event.

◆ Registration Desk

- **Location:**
Passage in front of "Kairaku", Main Building B1F
- **Opening Hours:**
 - July 11, 8:30–16:00
 - July 12, 7:00–17:00
 - July 13, 7:00–15:30

◆ Cloak

- **Location:** Next to the Registration Desk
- **Opening Hours:**
 - July 11, 8:30–17:00
 - July 12, 7:00–21:30
 - July 13, 7:00–17:30

◆ Wi-Fi Information

- Free Wi-Fi service is available at the venue.
- Network ID and Password are provided on-site.

2-2. For Chairs and Commentators of All Oral Sessions

Please be seated in the "Next Chair" or "Next Commentator" seat located at the front corner of your session room at least 15 minutes before the session starts.

For Chairs

As the chair of the session(s), please strictly control the process of your hosting session.

For Commentators

Commentators are not required to prepare slides or give a formal presentation. Your role is to ask questions and offer comments on the presentations to help enrich and stimulate the discussion.

2-3. For Invited Speakers and Oral Presentation Speakers

All speakers (including those using their own PC) are requested to visit the PC Preview Center to submit their presentation data at **least 30 minutes** before the start of their session.

◆ PC Preview Center

- **Location:**

Passage in front of "Kairaku 1", Main Building B1F

- **Opening Hours:**

- July 11, 8:30–16:00
- July 12, 7:00–17:00
- July 13, 7:00–15:30

2-3-1. Regarding Oral Presentations of Selected Abstracts

- **Allotted Time:** 10 minutes total – 7 minutes for the presentation, followed by 3 minutes for discussion.

2-3-2. Important Notes

1. All oral presentations should be digital (PC) presentations.
2. There is no limit to the number of presentation slides, but please make sure your presentation finishes within the allotted time.
3. Please use the keyboard or mouse on the podium to feed the slides.
4. If you have created your presentation using Windows, please save it on a USB drive or bring your own PC.
5. If you use a Mac, please bring your own PC.
6. Please submit your presentation and test it at the PC Center at least 30 minutes before the start of your session. If using your own PC, please note that after testing your presentation, your PC will be stored at the PC operation desk located on the left side of the lecture hall. You may register your data in advance to your presentation date.

2-3-3. How to create your presentation data

A PC Projectors will be used for presentations. Please see the details below.

- 1) Only computers with Windows 10 OS are provided at the venue.
- 2) Please bring your presentation data to the PC Preview Center on a USB flash drive. As a precautionary measure, we recommend that you double-check beforehand to see if the data stored on the USB drive works properly on a different PC.
- 3) A monitor, a mouse, and a keyboard are provided on the podium. Speakers should operate the peripheral devices for PowerPoint by themselves.
- 4) If you use a Macintosh computer to make your presentation, please bring your own laptop with your presentation data, or check if the data works properly on a Windows 10-based PC before the meeting to prevent any technical issues that may arise between the Windows and Macintosh operating systems. It is recommended that speakers who include video or sound files in their presentations bring and use their own laptops.
- 5) Please stop by the PC Preview Center at least 30 minutes before your session to submit your presentation data.
- 6) Presentations should adhere to the Code of Research Conduct and Research Ethics and rules on protecting personal information.
- 7) PowerPoint Presenter View cannot be used during the presentation. If you need a script for your presentation, please print it out and bring it to the venue. No printers are available for note printing in the venue.

B Things to Keep in Mind When Creating Presentation Slides.

- 1) Recommended slide size: 16:9 (4:3 is also supported for projection)
- 2) Please make your presentation data in English.
- 3) Please do not use any company logos or product logos on the presentation slides.
- 4) To the oral presenters of the Selected Abstracts, please include the program number assigned by the congress secretariat on the upper right of every slide in your presentation. (See the illustration on the right.)

(Example)



C Conflict of Interest (COI) disclosure

- At APPLE 2025, all speakers are requested to disclose all conflicts of interest (COI).
- Whether or not a speaker has any conflicts of interest (COI), they must include a COI disclosure slide on the first page of their presentation.
- Please note that the presentations without the COI disclosure will not be allowed. Please visit APPLE 2025's website to download the template.

D Data Submission

[If you bring your data on a USB flash drive]

- Please ensure that your presentation will display correctly on the systems with the following specifications:
 - OS: Windows 10
 - Software: PowerPoint 2021
 - Recommended slide size: 16:9 (4:3 is also supported for projection)
- 1) Fonts
Please use standard fonts of Windows 10 (OS) (e.g., Helvetica, Arial, Times New Roman) on your presentation slides, as unusual fonts may not be correctly displayed on the computers in the session rooms.
- 2) Movies
If you embed videos in your PowerPoint presentation data, please also bring the video files that can be played using the codecs in Windows Media Player's default settings. MP4 format is recommended. Please save the video data together in the same folder to maintain the links with PowerPoint.
- 3) Images
Please ensure images in your presentation data are in JPEG/TIFF/BMP format.
Do not include images in the standard Macintosh PICT format.
- 4) Graphs
To create graphs, please use standard PowerPoint functions or Excel graphs.
If you use other software, please paste the exported graph data into an image format described in the "Images" section above.
- 5) Anti-Virus Check
Please check the files using the latest anti-virus software before submitting them to the PC Preview Center.
- 6) Data
All speakers are requested to submit their presentation data to the PC Preview Center. The data will be temporarily stored on the server at "PC Reception" and on the computers at the venue, and will be deleted after the conference.

[If you bring your own PC]

- 1) Speakers using their own laptops MUST HAVE an AC adapter.
- 2) Speakers using their own laptops MUST HAVE an HDMI cable (Type A).
Please note that the mini D-sub 15-pin cable cannot be used.
If you need a converter to use an HDMI cable, please make sure to bring your own, as we will not be able to provide any.

- 3) Please turn off the modes that will hinder presentation beforehand, such as the screen-saver and energy-saving modes.
- 4) You should have your data backed up in case of computer trouble.
- 5) After having your computer/presentation data checked at the PC Preview Center, please bring your computer to the operation desk near the "Next Chair" seat in your session room no later than 15 minutes before your presentation.
Mirroring will be conducted at the operation desk, so please use the monitor, the mouse, and the clicker on the podium that the Secretariat provides to operate your slides. Please remember to get your laptop back from the operation desk after your presentation.
- 6) Please check your laptop using the latest anti-virus software before bringing it to the PC Preview Center.

2-4. For Poster Presentations

2-4-1. Schedule for Poster Walk Session

Date & Time: July 12, 16:00-17:00

Venues: Main Building B1F


- Poster Room 1 "Kikusui" P-001~P-039
- Poster Room 2 "Nunobiki" & "Kitano" P-040~P-133
- Poster Room 3 "Ikuta" P-134~P-208

Important Information:

- **No Oral Presentation Required:** There will be no oral presentations during the Poster Walk Session.
- **Stand by Your Poster:** Although no formal presentation is required, all presenters must be present at their assigned poster location by 15:55 on July 12 (i.e., 5 minutes before the session starts). Since this is a free walk session, you are welcome to move freely between the posters. However, we kindly ask that you make sure to attend to all of your accepted abstracts.

2-4-2. Poster Preparation

- Posters must be easily readable from a distance of 1 to 2 meters.
- The message should be clear and understandable without oral explanation.
- The poster title, author(s)' name(s), and affiliation(s) should be displayed prominently at the top.
- Content should follow the structure of the abstract.
- Each poster must be placed on the numbered board assigned to the presenter.
- Posters should be brought to the conference and not mailed, as the organizing committee is not responsible for any loss or mishandling.
- Presenters are responsible for setting up and removing their own posters.



2-4-3. Poster Dimensions

- The dimensions of the poster board are 90 cm wide x 210 cm high, and the size of the poster should be smaller than 85 cm wide x 185 cm high.
- Note that landscape posters or larger posters will not fit on the poster display boards and therefore, cannot be mounted.

☒ Size of poster board: 90 cm X 210cm

☒ Preferred size of poster: 85 cm X 185 cm


2-4-4. Poster Mount, Viewing, and Removal

- **Mount Time:**
 - July 12, 7:00–9:00
- **Viewing Time:**
 - July 12, 9:00–18:00
 - July 13, 7:00–15:30
- **Removal Time:**
 - July 13, 15:30–17:30

* Posters that are not removed by 18:00, will be removed and disposed of. As such, please make sure to take down your own poster. Any posters left will be discarded by the secretariat.

CONFERENCE FLOOR MAP

Kobe Portopia Hotel



FACULTY LIST

Asia

Shinichi Aishima	Kyushu University
Jun Akiba	Kurume University
Stephen Chan	The Chinese University of Hong Kong
Li-Tzong Chen	National Institute of Cancer Research, National Health Research Institutes (NHRI)
Ann-Lii Cheng	National Taiwan University Cancer Center
Tan To Cheung	The University of Hong Kong
Hong Jae Chon	CHA University
Su Pin Choo	National Cancer Centre Singapore
Pierce Chow	National Cancer Centre Singapore
Tomoki Ebata	Nagoya University
Susumu Eguchi	Nagasaki University
Jia Fan	Zhongshan Hospital, Fudan University
Takumi Fukumoto	Kobe University
Kenji Fukushima	Kobe University
Qiang Gao	Zhongshan Hospital, Fudan University
Kwang-Hyub Han	Yonsei University
Kiyoshi Hasegawa	Tokyo University
Etsuro Hatano	Kyoto University
Min-Ke He	Sun Yat-sen University Cancer Center
Atsushi Hiraoka	Ehime Prefectural Central Hospital
Tomoro Hishiki	Chiba University
Chih-Hung Hsu	National Taiwan University Hospital
Chiun Hsu	National Taiwan University Hospital

Yi-Hsiang Huang	National Yang Ming Chio Tung University
Masafumi Ikeda	National Cancer Center Hospital East
Hiroshi Imaoka	National Cancer Center Hospital East
Takamichi Ishii	Kyoto University
Shinji Itoh	Kyushu University
Masaki Kaibori	Kansai Medical University
Masashi Kanai	Kansai Medical University Hospital
Tomokazu Kawaoka	Hiroshima University
Do Young Kim	Yonsei University
Yoon Jun Kim	Seoul National University
Satoshi Kobayashi	Kanagawa Cancer Center
Takahiro Kodama	Osaka University
Norihiro Kokudo	National Center for Global Health and Medicine
Shohei Komatsu	Kobe University
Mina Komuta	International University of Health and Welfare, Narita Hospital
Ming Kuang	Sun Yat-sen University
Masatoshi Kudo	Kindai University
Hidekatsu Kuroda	Iwate Medical University
Masayuki Kurosaki	Japanese Red Cross Musashino Hospital
Teiji Kuzuya	Fujita Health University School of Medicine
Lian-Xin Liu	The First Affiliated Hospital of USTC
Shiro Miyayama	Fukuiken Saiseikai Hospital
Chigusa Morizane	National Cancer Center Hospital
Takamichi Murakami	Kobe University
Atsushi Nanashima	Miyazaki University

Irene Ng	The University of Hong Kong
Naoshi Nishida	Kindai University
Sadahisa Ogasawara	Chiba University
Do-Youn Oh	Seoul National University
Akihiro Ohba	Shizuoka Cancer Center
Kazuyoshi Ohkawa	Osaka International Cancer Institute
Naoko Ohtani	Osaka Metropolitan University
Takuji Okusaka	National Cancer Center Hospital
Masayuki Otsuka	Chiba University
Masato Ozaka	Cancer Institute Hospital of JFCR
Joong Won Park	Myongji Hospital
Young Nyun Park	Yonsei University
Hyunchul Rhim	Samsung Changwon Hospital, Sungkyunkwan University
Michiie Sakamoto	International University of Health and Welfare
Tomoyuki Satake	National Cancer Center Hospital East
Jinsil Seong	Yonsei University
Ying-Chun Shen	National Taiwan University Cancer Center
Ming Shi	Sun Yat-sen University Cancer Center
Ying-Hong Shi	Zhongshan Hospital, Fudan University
Satoshi Shiba	National Cancer Center
Taro Shibuki	National Cancer Center Hospital East
Satoshi Shimizu	Saitama Cancer Center
Junichi Shindoh	Toranomon Hospital
Kyung-Suk Suh	Seoul National University
Yutaka Suzuki	The University of Tokyo
Toshifumi Tada	Kobe University
Akinobu Taketomi	Hokkaido University

Shinji Tanaka	Institute of Science Tokyo
Ryosuke Tateishi	Tokyo University
Takeshi Terashima	Kanazawa University
Yosuke Togashi	Okayama University
Kaoru Tsuchiya	Japanese Red Cross Musashino Hospital
Makoto Ueno	Kanagawa Cancer Center Research Institute
Eisuke Ueshima	Kobe University
Kazuomi Ueshima	Kindai University
Michiaki Unno	Tohoku University
Yutaka Yasui	Musashino Red Cross Hospital
Thomas Yau	The University of Hong Kong
Sheng-Long Ye	Zhongshan Hospital, Fudan University
Tomoaki Yoh	Kyoto University
Changhoon Yoo	University of Ulsan
Kengo Yoshimitsu	Fukuoka University
Tomoharu Yoshizumi	Kyushu University
Ming-Lung Yu	Kaohsiung Medical University
Zhao-Chong Zeng	Zhongshan Hospital, Fudan University
Wei Zhang	Tongji Medical College, Huazhong University of Science and Technology
Jian Zhou	Zhongshan Hospital, Fudan University
Andrew Zhu	Jiahui International Cancer Center

United States of America

Ghassan K Abou-Alfa	Memorial Sloan Kettering Cancer Center
William R. Jarnagin	Memorial Sloan Kettering Cancer Center
Linda Wong	University of Hawaii

PROGRAM AT A GLANCE

Friday, July 11, 2025

	Room A (Kairaku 1+2)	Room B (Kairaku 3)	Poster
7:00			
8:00			
9:00		Opening	
10:00		9:20-9:30 9:30-11:00 Session 1 CHANGES IN THE LANDSCAPE OF HCC	
11:00		11:00-11:15 Break 11:15-11:50 Session 2 APPLE ACADEMY: THE ROADS BEFORE US	
12:00		11:50-12:50 Luncheon Symposium <i>Sponsored by Eisai Co., Ltd.</i>	
13:00		12:50-14:45 Session 3 UNMET CLINICAL NEEDS IN HCC AND CURRENT CLINICAL RESEARCH DIRECTIONS	
14:00		14:45-15:00 Break 15:00-16:25 Session 4 FROM APPLE ACADEMY INTO THE FUTURE	
15:00		16:25-16:30 Closing Remarks	
16:00			
17:00			
18:00			
19:00			
20:00			
21:00			

Saturday, July 12, 2025

	Room A (Kairaku 1+2)	Room B (Kairaku 3)	Poster
7:00			
8:00	7:30-8:20 Breakfast Symposium 1 Reconsidering the future use of drug therapy in the era of combined immunotherapy <i>Sponsored by Eisai Co., Ltd.</i>		
	8:30-8:40	Opening Ceremony	
9:00	8:45-9:15 State of the Art Lecture 1.		
	9:15-10:30	9:15-10:30	9:00-18:00
10:00	Session 1a. Epidemiology and Medical Circumstance for HCC in Asian-Pacific region	Session 1b. Epidemiology and Basic Science / Translational Research in CCA	Poster Viewing
	10:30-10:45 Coffee Break		
11:00	10:45-12:05	10:45-12:05	
	Session 2a. Molecular Pathogenesis and Pathology in HCC	Session 2b. Locoregional Therapy for CCA	
12:00			
	12:30-13:20 Luncheon Symposium 1 The role of lenvatinib, synthesized in Japan, in the treatment of hepatocellular carcinoma <i>Sponsored by Eisai Co., Ltd.</i>	12:30-13:20 Luncheon Symposium 2 Advancing the Frontier: Systemic Therapy in Challenging HCC <i>Sponsored by Roche</i>	
13:00			
	13:30-14:00 State of the Art Lecture 2.		
14:00	14:00-15:15	14:00-15:15	
15:00	Session 3a. Surgery, and Liver Transplant for HCC	Session 3b. Systemic Therapy for CCA	
	15:20-15:50 State of the Art Lecture 3.		
16:00	15:50-16:00 Coffee Break		16:00-17:00
			Poster Presentation Session
17:00			
	17:10-18:30	17:10-18:30	
18:00	Session 4a. Locoregional Therapy for HCC	Session 4b. Rare Liver Tumors	
19:00	19:00-21:00 GALA Dinner (APPLE General Meeting)		
20:00			
21:00			

PROGRAM AT A GLANCE

Sunday, July 13, 2025

	Room A (Kairaku 1+2)	Room B (Kairaku 3)	Poster
7:00			
8:00	7:30-8:20 Breakfast Symposium 2 Criteria regarding surgical treatment in Japan and future treatment strategies for advanced HCC <i>Sponsored by Eisai Co., Ltd.</i>		
9:00	8:30-10:00 Session 5a. Systemic Therapy for Early-stage HCC	8:30-10:00 Session 5b. Debate session	9:00-17:00
10:00	10:00-10:15 Coffee Break		Poster Viewing
11:00	10:15-10:45 State of the Art Lecture 4.		
12:00	10:45-12:15 Session 6a. Systemic Therapy for Intermediate-stage HCC	10:45-12:15 Session 6b. Hepatology in HCC Management	
13:00	12:15-13:05 Luncheon Symposium 3 The Trend of Systemic Therapy and Multidisciplinary Treatment for Hepatocellular Carcinoma. <i>Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.</i>	12:15-13:05 Luncheon Symposium 4 A New Era in Systemic Therapy for Hepatocellular Carcinoma: Therapeutic Innovation with the Opdivo-Yervoy Combination <i>Sponsored by Bristol-Myers Squibb/ONO PHARMACEUTICAL CO., LTD.</i>	
14:00	13:15-14:45 Session 7a. Systemic Therapy for Advanced-stage HCC	13:15-14:45 Session 7b. Novel strategies for CCA: Others	
15:00	14:45-15:15 State of the Art Lecture 5.	14:45-15:15 State of the Art Lecture 6.	
16:00	15:15-15:30 Coffee Break		
17:00	15:30-16:30 Session 8a. Presentations of Selected Abstracts I	15:30-16:20 Session 8b. Presentations of Selected Abstracts II	
18:00	16:30-16:40 Closing Ceremony		
19:00			
20:00			
21:00			

AGENDA

Saturday, July 12, 2025

Room A (Kairaku 1+2)		
Time	Title	Faculty
7:00-7:30	Registration	
7:30-8:20	Breakfast Symposium 1 Reconsidering the future use of drug therapy in the era of combined immunotherapy <i>Sponsored by Eisai Co., Ltd.</i>	Chair: Naoya Sakamoto (Hokkaido) Speakers: Nobuhito Taniki (Tokyo), Takahiro Kodama (Osaka)
8:30-8:40	Opening Ceremony	Chairs: Takumi Fukumoto (Kobe), Michiie Sakamoto (Tokyo), Masafumi Ikeda (Kashiwa) APPLE president: Jian Zhou (Shanghai)
State of the Art Lecture 1.		Chair: Sheng-Long Ye (Shanghai)
8:45-9:15	Precision Diagnosis and Treatment of Hepatocellular Carcinoma	Jia Fan (Shanghai)
Session 1a. Epidemiology and Medical Circumstance for HCC in Asian-Pacific region		Chairs: Thomas Yau (Hong Kong), Kyung-Suk Suh (Seoul) Commentators: Kazuyoshi Ohkawa (Osaka), Hidekatsu Kuroda (Iwate)
9:15-9:25	Simultaneous Liver Venous Deprivation Following Hepatic Arterial Chemoembolization before Major Hepatectomy for Hepatocellular Carcinoma to Achieve Hypertrophy Liver Remnant	Lian-Xin Liu (Anhui)
9:25-9:35	Epidemiology of Liver Cancer in the Pacific Region	Linda Wong (Honolulu)
9:35-9:45	Management of Hepatocellular Carcinoma in Taiwan ~ the changed and unchanged over the past two decades	Chih-Hung Hsu (Taipei)
9:45-9:55	Changes in Epidemiology and Management of Hepatocellular Carcinoma in South Korea	Joong Won Park (Goyang)
9:55-10:05	Epidemiology and Medical Circumstances of HCC in Japan	Masayuki Kurosaki (Tokyo)
10:05-10:30	Discussion	
10:30-10:45	Coffee Break	
Session 2a. Molecular Pathogenesis and Pathology in HCC		Chairs: Michiie Sakamoto (Tokyo), Lian-Xin Liu (Anhui) Commentators: Shinji Tanaka (Tokyo), Jun Akiba (Kurume)
10:45-11:00	Update on the Molecular-Pathological Features of HCC	Young Nyun Park (Seoul)
11:00-11:15	Immune microenvironment in HCC	Yosuke Togashi (Okayama)
11:15-11:30	Target Discovery in HCC	Irene Ng (Hong Kong)
11:30-11:45	Delineating the Cellular Ecosystem of Hepatocellular Carcinoma with Microvascular Invasion through Immune-Radiomics Analysis	Ying-Hong Shi (Shanghai)
11:45-12:05	Discussion	

AGENDA

Saturday, July 12, 2025

Room A (Kairaku 1+2)		
Time	Title	Faculty
12:30-13:20	Luncheon Symposium 1 The role of lenvatinib, synthesized in Japan, in the treatment of hepatocellular carcinoma <i>Sponsored by Eisai Co., Ltd.</i>	Chair: Masayuki Kurosaki (Tokyo) Speakers: Issei Saeki (Yamaguchi), Hayato Nakagawa (Mie)
State of the Art Lecture 2.		Chair: Norihiro Kokudo (Tokyo)
13:30-14:00	A Global Call to Action to Reduce the Burden of Liver Cancer	Jian Zhou (Shanghai)
Session 3a. Surgery, and Liver Transplant for HCC		Chairs: Pierce Chow (Singapore), Zhao-Chong Zeng (Shanghai) Commentators: Susumu Eguchi (Nagasaki), Tomoharu Yoshizumi (Fukuoka)
14:00-14:15	Surgical resection combined with systemic therapy for advanced hepatocellular carcinoma	Kiyoshi Hasegawa (Tokyo)
14:15-14:30	State-of-the-Art Surgery for Hepatocellular Carcinoma: Surgeon Scientist's Viewpoint	Ming Kuang (Guangzhou)
14:30-14:45	New Trends in Liver transplant for HCC in the US	Linda Wong (Honolulu)
14:45-15:00	Conversion therapy for advanced hepatocellular carcinoma to liver resection or transplantation using a combination of systemic and loco-regional treatments	Ying-Hong Shi (Shanghai)
15:00-15:15	Discussion	
State of the Art Lecture 3.		Chair: Jinsil Seong (Seoul)
15:20-15:50	Hepatocellular carcinoma: What is the big picture? And are we seeing it?	Ghassan K Abou-Alfa (New York)
15:50-16:00	Coffee Break	
16:00-17:00	Poster Presentation Session	
Session 4a. Locoregional Therapy for HCC		Chairs: Min-Ke He (Guangzhou), Do Young Kim (Seoul) Commentators: Kengo Yoshimitsu (Fukuoka), Takeshi Terashima (Kanazawa)
17:10-17:25	Latest Topics of Ablation Therapy	Ryosuke Tateishi (Tokyo)
17:25-17:40	Latest Topics of TACE/TARE	Yoon Jun Kim (Seoul)
17:40-17:55	FOLFOX HAIC: The New Regimen of Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma	Ming Shi (Guangzhou)
17:55-18:10	Recent hot topics in radiation therapy; Clinical potential of immunomodulatory effect of radiation by the dose level	Jinsil Seong (Seoul)
18:10-18:30	Discussion	
19:00-21:00	GALA Dinner (APPLE General Meeting)	

Room B (Kairaku 3)		
Time	Title	Faculty
Session 1b. Epidemiology and Basic Science /Translational Research in CCA		Chairs: Stephen Chan (Hong Kong), Yoon Jun Kim (Seoul) Commentators: Hiroshi Imaoka (Kashiwa), Takeshi Terashima (Kanazawa)
9:15-9:30	Epidemiology	Chigusa Morizane (Tokyo)
9:30-9:45	Cholangiocarcinoma in the Spectrum of Primary Liver Cancers: Diagnostic and Therapeutic Insights from Pathology	Mina Komuta (Chiba)
9:45-10:00	Gene fusions generate potential therapeutic targets for iCCA	Qiang Gao (Shanghai)
10:00-10:15	Concordance of Circulating Tumor DNA and Tissue Genomic Profiling in Advanced Biliary Tract Cancer	Hong Jae Chon (Seongnam)
10:15-10:30	Discussion	
10:30-10:45	Coffee Break	
Session 2b. Locoregional Therapy for CCA		Chairs: Su Pin Choo (Singapore), Changhoon Yoo (Seoul) Commentators: Michiaki Unno (Sendai), Atsushi Nanashima (Miyazaki)
10:45-11:00	Current status and challenges in surgical management of intrahepatic cholangiocarcinoma	Masayuki Ohtsuka (Chiba)
11:00-11:15	Surgical management of cholangiocarcinoma	Tan To Cheung (Hong Kong)
11:15-11:30	Radiotherapy for intrahepatic cholangiocarcinoma in the era of immunotherapy	Zhao-Chong Zeng (Shanghai)
11:30-11:45	Hepatic artery infusion chemotherapy for IHC	William R. Jarnagin (New York)
11:45-12:05	Discussion	
12:30-13:20	Luncheon Symposium 2 Advancing the Frontier: Systemic Therapy in Challenging HCC <i>Sponsored by Roche</i>	Chairs: Masatoshi Kudo (Osaka), Ann-Lii Cheng (Taipei) Speakers: Ruibao Liu (Harbin), Stephen Lam Chan (Hong Kong)
Session 3b. Systemic Therapy for CCA		Chairs: Andrew Zhu (Shanghai), Chih-Hung Hsu (Taipei) Commentators: Masafumi Ikeda (Kashiwa), Masashi Kanai (Osaka)
14:00-14:15	Adjuvant chemotherapy for biliary tract cancer	Tomoki Ebata (Nagoya)
14:15-14:30	Systemic Therapy for Intrahepatic Cholangiocarcinoma: First-line	Li-Tzong Chen (Tainan)
14:30-14:45	Recent Updates for Second-Line Therapy in Advanced Biliary Tract Cancer (BTC)	Changhoon Yoo (Seoul)
14:45-15:00	Systemic therapy for CCA; Ongoing novel clinical trials	Do-Youn Oh (Seoul)

AGENDA

Saturday, July 12, 2025

Room B (Kairaku 3)		
Time	Title	Faculty
15:00-15:15	Discussion	
15:50-16:00	Coffee Break	
16:00-17:00	Poster Presentation Session	
Session 4b. Rare Liver Tumors		Chairs: Irene Ng (Hong Kong), Young Nyun Park (Seoul) Commentators: Takuji Okusaka (Tokyo), Shinichi Aishima (Fukuoka)
17:10-17:22	Combined Hepatocellular-Cholangiocarcinoma: Diagnosis and Systemic Treatment	Tomoyuki Satake (Kashiwa)
17:22-17:34	Fibrolamellar carcinoma	Ghassan K Abou-Alfa (New York)
17:34-17:46	Comprehensive Clinicopathological and Whole-Exome Analysis of Cholangiolocarcinoma	Takamichi Ishii (Kyoto)
17:46-17:58	Epithelioid hemangioendothelioma, an ultra-rare soft tissue sarcoma: recent topics of interest	Satoshi Shiba (Tokyo)
17:58-18:10	Hepatoblastoma and Pediatric Liver Tumors: Distinct Biology, Global Collaboration, and Evolving Strategies	Tomoro Hishiki (Chiba)
18:10-18:30	Discussion	

Sunday, July 13, 2025

Room A (Kairaku 1+2)		
Time	Title	Faculty
7:00-7:30	Registration	
7:30-8:20	Breakfast Symposium 2 Criteria regarding surgical treatment in Japan and future treatment strategies for advanced HCC <i>Sponsored by Eisai Co., Ltd.</i>	Chair: Norihiro Kokudo (Tokyo) Speakers: Junichi Shindoh (Tokyo), Shohei Komatsu (Kobe)
Session 5a. Systemic Therapy for Early-stage HCC		Chairs: Ming Kuang (Guangzhou), Qiang Gao (Shanghai) Commentators: Akinobu Taketomi (Sapporo), Makoto Ueno (Tokyo)
8:30-8:45	Adjuvant Therapy after Loco-regional Treatment in Hepatocellular Carcinoma	Pierce Chow (Singapore)
8:45-9:00	Evolving Landscape and Evidence for Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma	Wei Zhang (Wuhan)
9:00-9:15	Treatment Strategy for Borderline Resectable Hepatocellular Carcinoma	Tomoaki Yoh (Kyoto)
9:15-9:30	Perioperative treatment of Liver Transplant	Kyung-Suk Suh (Seoul)
9:30-9:45	The Potential Role of Systemic Therapy in Early-Stage Hepatocellular Carcinoma: A Special Clinical Consideration	Kaoru Tsuchiya (Tokyo)
9:45-10:00	Discussion	
10:00-10:15	Coffee Break & Poster Viewing	
State of the Art Lecture 4.		Chair: Masatoshi Kudo (Osaka)
10:15-10:45	Current status and Future perspectives of multidisciplinary treatment for advanced HCC in Kobe University	Takumi Fukumoto (Kobe)
Session 6a. Systemic Therapy for Intermediate-stage HCC		Chairs: Joong Won Park (Goyang), Ming Shi (Guangzhou) Commentators: Takamichi Murakami (Kobe), Teiji Kuzuya (Nagoya)
10:45-11:00	TACE refractoriness and TACE unsuitability	Do Young Kim (Seoul)
11:00-11:15	Is systemic therapy alone feasible for intermediate-stage HCC?	Yi-Hsiang Huang (Taipei)
11:15-11:30	Combination therapy of TACE with Systemic therapy	Masatoshi Kudo (Osaka)
11:30-11:45	Utilizing the conversion concept based on disease status following systemic chemotherapy for hepatocellular carcinoma	Shohei Komatsu (Kobe)
11:45-12:00	Optimizing Immunotherapy: Radiologist's Perspective	Eisuke Ueshima (Kobe)
12:00-12:15	Discussion	

AGENDA

Sunday, July 13, 2025

Room A (Kairaku 1+2)		
Time	Title	Faculty
12:15-13:05	Luncheon Symposium 3 The Trend of Systemic Therapy and Multidisciplinary Treatment for Hepatocellular Carcinoma <i>Sponsored by CHUGAI PHARMACEUTICAL CO.,LTD.</i>	Chair: Masafumi Ikeda (Chiba) Speakers: Takanori Ito (Nagoya), Sadahisa Ogasawara (Chiba)
Session 7a. Systemic Therapy for Advanced-stage HCC		Chairs: Kwang-Hyub Han (Seoul), Sheng-Long Ye (Shanghai) Commentators: Atsushi Hiraoka (Matsuyama), Toshifumi Tada (Kobe)
13:15-13:30	First-Line Therapy	Thomas Yau (Hong Kong)
13:30-13:45	Second-line therapy for unresectable hepatocellular carcinoma (HCC)	Chiun Hsu (Taipei)
13:45-14:00	Evolving strategies for late-line treatment in advanced hepatocellular carcinoma	Sadahisa Ogasawara (Chiba)
14:00-14:15	Locoregional Treatment in Advanced HCC: Moving Toward a New Necessity	Hyunchul Rhim (Changwon)
14:15-14:30	Trends in Drug Development for HCC	Ann-Lii Cheng (Taipei)
14:30-14:45	Discussion	
State of the Art Lecture 5.		Chair: Ann-Lii Cheng (Taipei)
14:45-15:15	Navigating the optimal management of HCC	Kwang-Hyub Han (Seoul)
15:15-15:30	Coffee Break & Poster Viewing	
Session 8a. Presentations of Selected Abstracts I		Chairs: Jian Zhou (Shanghai), Masayuki Kurosaki (Tokyo) Commentators: Takahiro Kodama (Osaka), Kenji Fukushima (Kobe)
15:30-15:40	Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab	Masaki Omori (Kobe)
15:40-15:50	The usefulness of the non-invasive scoring systems for the hepatocarcinogenesis in patients with MASLD/MASH	Takashi Nishimura (Hyogo)
15:50-16:00	Tumor Budding Predicts Poor Survival in Hepatocellular Carcinoma Patients Treated with Neoadjuvant/Conversion Therapy: A Cohort Study Using ITBCC Criteria	Pu-Wen Shen (Shanghai)
16:00-16:20	Discussion	
16:20-16:30	Awards ceremony	
Closing Ceremony		Chairs: Takumi Fukumoto, Michiie Sakamoto, Masafumi Ikeda
16:30-16:40	Summary of APPLE 2025 & Introduction of APPLE 2026	Jian Zhou (Shanghai)

Room B (Kairaku 3)		
Time	Title	Faculty
Session 5b. Debate session		Chairs: Tan To Cheung (Hong Kong), Yi-Hsiang Huang (Taipei) Commentators: Kazuomi Ueshima (Osaka), Shinji Itoh (Fukuoka)
8:30-8:40	Case 1. Treatment strategy combining ICI chemotherapy and surgery for advanced hepatocellular carcinoma	Masaki Kaibori (Osaka)
8:40-8:50	Case 1. Borderline resectable HCC: Neoadjuvant therapy	Etsuro Hatano (Kyoto)
8:50-9:00	Case 2. Conversion possible: resection	Junichi Shindoh (Tokyo)
9:00-9:10	Case 2. Conversion possible: Continue systemic therapy	Satoshi Kobayashi (Yokohama)
9:10-9:20	Case 3. Some up-to-7 out hepatocellular carcinomas can be cured by transarterial chemoembolization alone	Shiro Miyayama (Fukui)
9:20-9:30	Case 3. Intermediate HCC: TACE+Systemic therapy	Stephen Chan (Hong Kong)
9:30-9:40	Case 4. Advanced stage HCC with Vp4: Systemic therapy	Yutaka Yasui (Tokyo)
9:40-9:50	Case 4. Advanced stage HCC with Vp4: FOLFOX-HAIC	Min-Ke He (Guangzhou)
9:50-10:00	Discussion	
10:00-10:15	Coffee Break & Poster Viewing	
Session 6b. Hepatology in HCC Management		Chairs: Andrew Zhu (Shanghai), Ryosuke Tateishi (Tokyo) Commentators: Masato Ozaka (Tokyo), Tomokazu Kawaoka (Hiroshima)
10:45-11:00	Clinical Feasibility of Circulating Tumor DNA in Advanced Hepatocellular Carcinoma	Hong Jae Chon (Seongnam)
11:00-11:15	Novel Biomarkers on Immunotherapy Treatment for Unresectable HCC	Takahiro Kodama (Osaka)
11:15-11:30	Gut-liver axis-mediated mechanism of liver cancer development: gut microbial components alter liver tumor microenvironment	Naoko Ohtani (Osaka)
11:30-11:45	Factors Influencing Immune Checkpoint Inhibitor Efficacy	Taro Shibuki (Kashiwa)
11:45-12:00	Disparities between viral versus metabolic HCC	Ming-Lung Yu (Kaohsiung)
12:00-12:15	Discussion	
12:15-13:05	Luncheon Symposium 4 A New Era in Systemic Therapy for Hepatocellular Carcinoma: Therapeutic Innovation with the Opdivo–Yervoy Combination <i>Sponsored by Bristol-Myers Squibb/ONO PHARMACEUTICAL CO., LTD.</i>	Chair: Masayuki Kurosaki (Tokyo) Speaker: Masatoshi Kudo (Osaka)

AGENDA

Sunday, July 13, 2025

Room B (Kairaku 3)		
Time	Title	Faculty
Session 7b. Novel strategies for CCA: Others		Chairs: Do-Youn Oh (Seoul), Masafumi Ikeda (Kashiwa) Commentators: Hiroshi Imaoka (Kashiwa), Masashi Kanai (Kyoto)
13:15-13:30	Transplantation for Advanced IHC	William R. Jarnagin (New York)
13:30-13:45	Noval Targets of Cholangiocarcinoma	Ying-Chun Shen (Taipei)
13:45-14:00	Molecular Heterogeneity in CCA and predictive biomarkers	Su Pin Choo (Singapore)
14:00-14:15	Immune Landscape of Intrahepatic Cholangiocarcinoma and its Clinical Implication	Naoshi Nishida (Osaka)
14:15-14:30	Optimal Dose of Immune Checkpoint Inhibitor – Flat-, Body-weight based-, or Low-dose?	Li-Tzong Chen (Tainan)
14:30-14:45	Discussion	
State of the Art Lecture 6.		Chair: Chiun Hsu (Taiwan)
14:45-15:15	Towards Multi-Omics Spatial Analysis to Reveal Cancer Heterogeneity	Yutaka Suzuki (Kashiwa)
15:15-15:30	Coffee Break & Poster Viewing	
Session 8b. Presentations of Selected Abstracts II		Chairs: Ming-Lung Yu (Kaohsiung), Makoto Ueno (Tokyo) Commentators: Masato Ozaka (Tokyo), Satoshi Shimizu (Saitama)
15:30-15:40	Dose-Response Association Between Body Mass Index and the Risk of Cholangiocarcinoma	Joo-Hyun Park (Korea)
15:40-15:50	Survival Outcomes of Transarterial Treatment versus Systemic Therapy as Initial Treatment for Hepatocellular Carcinoma with Extrahepatic Metastasis	Jaejun Lee (Korea)
15:50-16:00	Reconstructing Exosomal Biomechanical Signatures from RNA Profiles to Predict Hepatocellular Carcinoma Progression: A Deep Learning-Based Approach	Rifaldy Fajar (Indonesia)
16:00-16:20	Discussion	
(Awards ceremony, move to Room A)		

POSTER SESSIONS

- **Location:** Main Building B1F
- **Date & Time:** Saturday, July 12 | **16:00 – 17:00**
- **Poster Room Assignments:**
 - Poster Room 1: "Kikusui" (Posters P-001 ~ P-039)
 - Poster Room 2: "Nunobiki" & "Kitano" (Posters P-040 ~ P-133)
 - Poster Room 3: "Ikuta" (Posters P-134 ~ P-208)

No.	Abstract Title	Presenters
P-001	Development of a deep learning-based algorithm for fat quantification using proton density fat fraction maps in liver MRI	Ja Kyung Yoon
P-002	Reconstructing Exosomal Biomechanical Signatures from RNA Profiles to Predict Hepatocellular Carcinoma Progression: A Deep Learning-Based Approach	Rifaldy Fajar
P-003	The consequently annual prediction of HCC recurrence after partial hepatectomies with artificial intelligence	Ming-Chin Yu
P-004	Using Machine Learning to Predict High-Risk Populations Among Hepatocellular Carcinoma Patients	Chun-Ying Wang
P-005	Validation for the Efficacy of AI Platforms on Liver Cancer Treatment Strategies	Keungmo Yang
P-006	A Machine Learning Model for Predicting Hepatocellular Carcinoma in Patients with MASLD	Han Ah Lee
P-007	<i>Withdrawal</i>	
P-008	Tumor Budding Predicts Poor Survival in Hepatocellular Carcinoma Patients Treated with Neoadjuvant/Conversion Therapy: A Cohort Study Using ITBCC Criteria	Pu-Wen Shen
P-009	Analysis of Antidrug Antibodies (ADA) to Camrelizumab in CARES-310: The Study of Camrelizumab + Rivoceranib in Unresectable Hepatocellular Carcinoma (uHCC)	Stephen L Chan
P-010	The Slope of Reduced Serum PIVKA-II Predicts The Responses of Immunotherapy in Hepatocellular Carcinoma Patients	Huang-Pin Chen
P-011	Association of Alpha-fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with Camrelizumab + Rivoceranib vs Sorafenib (CARES-310)	Stephen L Chan
P-012	Using Next-Generation Sequencing to Predict Anti-PD-(L)1 Response in Hepatocellular Carcinoma	San-Chi Chen
P-013	Exosomal miR-30a-5p for Predicting Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma	Eunho Choi
P-014	CT-derived Body Composition as a Prognostic Biomarker in Early-Stage Hepatocellular Carcinoma: Insights from Volumetric and Single-Slice Assessments	Seok Jin Hong
P-015	Liver Stiffness by VCTE Predicts Hepatic Decompensation and Differential Efficacy of Atezolizumab-Bevacizumab versus TKIs in Advanced Hepatocellular Carcinoma	Jaejun Lee
P-016	Impact of Interleukin-6 and -8 on Treatment Efficacy of Bevacizumab plus ICIs and Interventional Therapy in patients with unresectable HCC	Tong Li
P-017	PVR Expression Associated with Unique Tumor Microenvironment in Hepatocellular Carcinoma	Li-Chun Lu

P-018	Distribution, density and composition of tertiary lymphoid structures predict clinical outcome in liver cancer	Jiaqiang Ma
P-019	Magnetic Resonance Imaging Radiomics for Predicting Hepatocellular Carcinoma Recurrence Following Resection or Ablation: A Systematic Review and Meta-analysis	Soe Thiha Maung
P-020	Development of Pathological Prediction Models for Extrahepatic Metastasis of Hepatocellular Carcinoma	Ji Hae Nahm
P-021	Usefulness of perioperative peripheral blood GPC3-positive circulating tumor cells in subclassification of Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma	Yosuke Namba
P-022	The usefulness of the non-invasive scoring systems for the hepatocarcinogenesis in patients with MASLD/MASH	Takashi Nishimura
P-023	Serum full-length glypican 3 predicts therapeutic response and survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	Naoshi Odagiri
P-024	Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab	Masaki Omori
P-025	Explainable Deep Learning for Ultra-Early Detection of Hepatocellular Carcinoma via Multi-Omics Integration of Single-Cell Transcriptomics and DNA Methylation Signatures	Prihantini Prihantini
P-026	Albumin-Butyrylcholinesterase (ABC) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Multi-Center Retrospective Cohort Study	Takeshi Tadokoro
P-027	Tumor-Stroma Ratio as a Prognostic Indicator in HCC: Multi-Omics Insights into the Tumor Microenvironment and Prediction of Neoadjuvant Therapy Response	Yangyang Xie
P-028	HBV DNA Level Change is Associated With Tumor Recurrence in Patients With Resected HBV related Hepatocellular Carcinoma	Tae Yoo
P-029	ACSL4 as a Biomarker for Assessing the Metastatic and Recurrence Propensity of Hepatocellular Carcinoma: Insights from a Multicenter Study	Maimaitiniyati Yusufukadier
P-030	Tumor-infiltrating lymphocyte abundance refines prognosis in patients with hepatocellular carcinoma	Zehong Zhang
P-031	Genomic Instability and EGFR Amplification as Mechanisms of Lenvatinib Resistance in Hepatocellular Carcinoma	Wonseok Kang
P-032	Functional and Spatial Polarization of Cancer-Associated Fibroblasts in the Tumor Microenvironment of Hepatocellular Carcinoma	Takahiro Nishio
P-033	Spatially-Aware AI Framework Identifies Hypoxia-Induced Metabolic Zonation Collapse as a Driver of Immune Exclusion in Hepatocellular Carcinoma	Sahnaz Vivinda Putri
P-034	Patient-Derived Organotypic Tumor Spheroids Enable Rapid Drug Evaluation in Hepatocellular Carcinoma	Fei Song
P-035	Dendritic Cell Mediated CD8+ T Cell Priming Prolongs Yttrium-90-radioembolisation Efficacy in Hepatocellular Carcinoma	Xiaojuan Wang
P-036	Charting single-cell metabolism co-evolution during metastasis	Yingcheng Wu
P-037	Assessment of Shear Wave Velocity and Predictors of Liver Fibrosis Improvement in HBV-Induced Cirrhosis Treated with Tenofovir Disoproxil Fumarate	Tien K H
P-038	Diagnostic usefulness of point-of-care ultrasound in detecting newly developed ascites in patients with liver cirrhosis	Seungteak Lee
P-039	Effects of cirrhosis on long-term survival of patients with early and middle stage HBV-related hepatocellular carcinoma: a multicenter, cohort study	Yongshuai Wang
P-040	Integrating CT-Based Radiomics and Machine Learning to Predict Immunotherapy Response in Advanced Hepatocellular Carcinoma	Bang-Bin Chen

P-041	Postoperative Recovery in Liver Disease: The Role of Caregiver Perception, Knowledge, and Attitude	Hepri Ardianson
P-042	<i>Withdrawal</i>	
P-043	<i>Withdrawal</i>	
P-044	Diagnostic Accuracy and Safety of EUS-Guided Liver Biopsy in the Endoscopic Hepatology Era: A Single-Center Experience	Dong Wook Kim
P-045	Identifying the high-risk group of MASH-related HCC using MR elastography	Shohei Kimura
P-046	<i>Withdrawal</i>	
P-047	The Role of Radiogenomics in Early-Stage Liver Cancer Screening	Yesika Simbolon
P-048	Comparative performance of gadoxetic acid-enhanced MRI and extracellular contrast agent-enhanced MRI for diagnosing subcentimeter recurrent HCC: a modified algorithm	Yuyao Xiao
P-049	Detection and Characterization of Subcentimeter Hepatocellular Carcinoma: A Comparison of Gadoxetic Acid-Enhanced and Extracellular Contrast Agent-Enhanced MRI	Yuyao Xiao
P-050	Hepatocellular Carcinoma in Southern Taiwan: Report from a Tertiary Medical Center	Chia-Yen Dai
P-051	Cyanotoxins and Metabolic-Associated Hepatocellular Carcinoma	Brenda Y. Hernandez
P-052	Prognostic Impact of Diabetes and Hypertension on Hepatocellular Carcinoma Survival: A 15-Year Registry-Based Analysis	Hyeyeon Hong
P-053	An Evaluation of Long-Term Fasting Effects on Preoperative and Postoperative Outcomes in Liver Surgery	Helen Try Juniasti
P-054	Predictive Value of OGTT for Hepatocellular Carcinoma in Liver Cirrhosis: A Prospective Observation	Seong Hee Kang
P-055	Alcohol-related liver disease in liver transplantation	Hyo-Sin Kim
P-056	Socioeconomic factors for poor compliance with hepatocellular carcinoma surveillance in patients with chronic hepatitis B	Jung Hee Kim
P-057	US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis	Sunyoung Lee
P-058	Pediatric Malignant Neoplasm of Liver; Nationwide Cohort Study of Korea	Jihye Lim
P-059	Dose-Response Association Between Body Mass Index and the Risk of Cholangiocarcinoma	Joo-Hyun Park
P-060	Risk factors and prolonged survival in liver cancer patients undergoing immunotherapy: A multivariate regression analysis	Ester Marnita Purba
P-061	Impact of Waiting Time Before Surgery on Survival in Bile Tract Cancer	Diana Elena Renteria Ramirez
P-062	<i>Withdrawal</i>	
P-063	Aging in Place for Elderly with Liver Conditions Undergoing Laparoscopic Procedures: Informal Caregivers Roles in Maintaining Quality of Life	Lintong Hottua Simbolon
P-064	Nonlinear Association Between Serum Vitamin D Status and Liver Disease Risk: A US Cohort Study	Yuan-Tsung Tseng
P-065	Association of Vitamin D Deficiency on Liver Disease and Mortality: A US Cohort Study	Yuan-Tsung Tseng
P-066	Impact Evaluation of Policy Interventions on Liver Disease Prevalence: Assessing the Smoking and Alcohol Regulation in Indonesia	Hepri Ardianson
P-067	The Influence of COVID-19 on Hepatocellular Carcinoma Was Investigated Using Bioinformatics and Systems Biology Techniques	XianXiang Chen

P-068	Early Detection occurrence and recurrence, Prompt Treatment, Re-treatment, Multidisciplinary Care in Long-term of hepatocellular carcinoma: Roles of modifiable medical interventions	Kuan Chen Pan
P-069	Hepatocellular carcinoma following direct-acting antiviral therapy in Korean patients with HBV/HCV co-infection	Youngjoo Park
P-070	Cost-Effectiveness Analysis of Laparoscopic Liver Resection (LLR): Therapeutic Efficacy and Socioeconomic Outcomes	Yesika Simbolon
P-071	The Effect of <i>Clostridium</i> Strains on Liver Cancer Strains on Liver Cancer	Sang Jun Yoon
P-072	Transcriptomic and tumor immune microenvironment profiling of steatohepatic, burned-out steatohepatic, and scirrhou hepatocellular carcinomas	Taek Chung
P-073	LncRNA CDKN2B-AS1 Genetic Variants are Associated with Progression of Hepatocellular Carcinoma	Kuan-Chun Hsueh
P-074	Three-dimensional vascular structure of hepatocellular carcinoma revealed by tissue clearing method and relationship with immune microenvironment	Yutaka Kurebayashi
P-075	Cathepsin A is critical in regulating cell growth of hepatocellular carcinoma via stabilizing Bcl-2	Zhuan Li
P-076	Radiation-induced SA- β Gal+ Hepatoma Cells Inhibit Tumor Immunity Through Promoting Neutrophils N2 Polarization	Jiaoyang Yang
P-077	Reconstruction of the Metabolism of β -hydroxybutyric Acid Accelerates the Progression of Hepatocellular Carcinoma through β -hydroxybutyrylation Modification	Zijan Zhang
P-078	Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression	Jinqiu Zhao
P-079	Pathological features and metabolic risk factors associated with immune-related liver injury induced by immune checkpoint inhibitors	Ryo Izai
P-080	Assessment of Liver Fibrosis in Alcoholic Liver Disease Using ARFI Elastography	Le Thi Thu Hien
P-081	Iron-Corrected T1 as a Predictor of Extrahepatic Cancer Risk: A UK Biobank Study	Tae Seop Lim
P-082	Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Obstructive Sleep Apnea	Sang Yi Moon
P-083	Utility of Complete Blood Count-Derived Inflammatory Indices for Predicting Metabolic- Associated with Fatty Liver Diseases in a Korean Population	Kyoung-Jin Park
P-084	Incidence and Management of Hepatic Immune-Related Adverse Events in Advanced Urologic Cancers Treated with Immune Checkpoint Inhibitors	Youngjoo Park
P-085	Radiotherapy Confers 5-FU Resistance in intrahepatic cholangiocarcinoma Cells	Shuxuan Wang
P-086	Single-center experience of Two-step liver resection in treatment of advanced hepatic echinococcosis	Hongming Xing
P-087	A single arm phase II trial of tislelizumab plus adaptive chemotherapy in biliary tract cancer (BTC) patients with lymphatic metastasis	Bin Yi
P-088	Differentiation of Epithelioid Hepatic Angiomyolipoma from Hepatocellular Carcinoma on MR Imaging in Patients with Hepatitis B based on LI-RADS v2018	Yangli Yu
P-089	cGAS-STING-ARG1 Axis Drives CD8+ T Cell Dysfunction in Radiation-Induced Liver Injury	Pan Zhou
P-090	Machine-learning algorithms for predicting hepatic steatosis grades in Chinese non-obese population	Yitong Zhu
P-091	Impact of Age on Treatment Uptake and Survival in Elderly Patients With Hepatocellular Carcinoma	Jang Eun Sun

P-092	Dynamic Prognostic Nomogram for Conditional Survival in Hepatocellular Carcinoma: An Analysis from the Korea Liver Cancer Registry	Jae Hyun Kwon
P-093	Prognostic Value of Sarcopenia on the Recurrence of Hepatic Encephalopathy	Sang Hun Park
P-094	Role of ALBI score as a predictive factor for mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization	Won Sohn
P-095	Comparative Prognostic Value of Albumin-Bilirubin Grade, PALBI, and MELD 3.0 in Hepatocellular Carcinoma Patients with Renal Insufficiency	Myeong Jun Song
P-096	Clinical Characteristics of Progression and Prognosis in Hepatocellular Carcinoma with Underlying Alcohol-Related Liver Disease	Takahiro Tsuchiya
P-097	Prognosis of Systemic Therapy Based on Oncological Resectability Criteria	Yutaka Yasui
P-098	Prognostic Value of Preoperative Osteopenia in Hepatocellular Carcinoma	Xudong Zhang
P-099	Arterial infusion chemotherapy plus apatinib in second-line therapy for hepatocellular carcinoma with extrahepatic metastasis	Shiguang Chen
P-100	Drug-eluting Beads Transcatheter Arterial Chemoembolization Plus Adebrelimab and Apatinib in Hepatocellular Carcinoma with PVTT: A Single-arm, Exploratory Trial	Tao Han
P-101	<i>Withdrawal</i>	
P-102	Yttrium-90 Combined with Donafenib and Immune Checkpoint Inhibitors for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Trial in Progress	Sulai Liu
P-103	Safety and Efficacy of Lenvatinib ± TACE as Conversion Therapy for Potentially Resectable HCC Patients: A Double-arm, Prospective Study	Hui-Chuan Sun
P-104	Prospective Observational Study on Systemic Therapy for Unresectable Hepatocellular Carcinoma (PRISM Study): An Update Analysis of First 1,000 patients	Tomokazu Kawaoka
P-105	Pseudo-Progression of Metastatic Hepatocellular Carcinoma in a Subject Who Received Glypican-3-targeting Engineered T Cell Therapy: Serial Imaging and Laboratory Findings	Jui-Che Chen
P-106	Barbituric Acid Derivative Ameliorates MAFLD-induced Liver Cancer and Mood Disorders in Mice	Yi-Jen Liao
P-107	Treatment strategy for Colorectal liver metastases based on liver resection and the benefit of preoperative chemotherapy	Toshihiko Yoshida
P-108	Impact of Initial Hepatectomy With Hilar Manipulation on Short-Term Outcomes of Repeat Hepatectomy for Recurrent Liver Cancer	Keisuke Arai
P-109	Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation	Jai Young Cho
P-110	Impact of Post-Hepatectomy Liver Failure on Long-Term Liver Function and Prognosis in Patients with Hepatocellular Carcinoma	Kenji Fukushima
P-111	Impact of Multimodal Treatment and Conversion Surgery in Advanced Hepatocellular Carcinoma Based on BR Classification	Naruhiko Honmyo
P-112	ABO blood type has no effect on HCC recurrence after LDLT in the Korean Organ Transplantation Registry study	Jongman Kim
P-113	Results of Laparoscopic Versus Open Major Hepatectomy for Hepatocellular Carcinoma in a Vietnamese Tertiary Hospital: A Five-Year Retrospective Comparative Study	Trung-Hieu LE
P-114	In Vivo Multi-organ Hypothermic Perfusion and Autotransplantation for Treating Tumors Invading the Superior Visceral Artery Segment of Abdominal Aorta	Peng Li
P-115	Association between cisterna chyli diameter and perioperative factors in patients undergoing hepatectomy for hepatocellular carcinoma	Daijiro Matoba

P-116	Cytoreductive surgery for advanced Hepatocellular carcinoma with macrovascular thrombosis unresponsive to systemic therapy: A case report.	Nguyen Truong Giang
P-117	Advances and Challenges in Liver Transplantation: The Laparoscopic Potential for Intraoperative Risk Reduction and Recovery improvements.	Ester Marnita Purba
P-118	Evaluation of Nutritional Risk Assessment Methods for Hepatectomy in Hepatocellular Carcinoma	Kentaro Oji
P-119	A Case of Successful Conversion Hepatectomy Following Durvalumab plus Tremelimumab Therapy under Nasogastric Feeding for Advanced Vp4 Hepatocellular Carcinoma	Hayata Sano
P-120	Network meta-analysis of prognostic performance of expanded criteria for liver donors with hepatocellular carcinoma	Ju Hyun Shim
P-121	Analysis of the Relation between Tumor Location and Surgical Outcomes in Hepatocellular Carcinoma	Daisuke Taguchi
P-122	Comparative long-term outcomes of minimally invasive hepatectomy and open hepatectomy: How health behaviors could affect the overall qol?	Lintong Hottua Simbolon
P-123	Impact of tumor size on liver regeneration after hepatectomy	Daisuke Takimoto
P-124	Efficacy and safety of adefrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a single-arm, phase II study	Guang Tan
P-125	Laparoscopic right posterior sectionectomy using the anterior approach for huge hepatocellular carcinoma	Takeshi Urade
P-126	Validation of 3 borderline resectable hepatocellular carcinoma models	Linda L Wong
P-127	Efficacy and Safety of Preoperative Neoadjuvant Systemic Therapy for CNLC Stage Ib - IIIa Hepatocellular Carcinoma: A Retrospective Study	Xiaozhun Huang
P-128	Clinical factors Associated with Resection Rate and Survival After Conversion Therapy with HAIC Combined with Targeted-Immunotherapy for Unresectable HCC	Yuchen Yang
P-129	Preoperative circulating tumor cells indicate microvascular invasion and dynamical detection indicate the early recurrence of hepatocellular carcinoma	Xiaozhun Huang
P-130	Liver Resection Using In Situ Hypothermic Portal Perfusion Without Venovenous Bypass for the Treatment of Bismuth Type IV Hilar Cholangiocarcinoma	Xinyu You
P-131	Characteristics and risk factors of extrahepatic recurrence after hepatectomy of hepatocellular carcinoma without intrahepatic hepatocellular carcinoma: A multi-institutional observational study	Jae Hyun Yoon
P-132	Liver transplantation after radiotherapy-antiangiogenesis-immune checkpoint blockade combination therapy in hepatocellular carcinoma with major PVTT: A propensity score matching analysis	Ying Zhao
P-133	Extrahepatic recurrence after surgical resection of hepatocellular carcinoma without intrahepatic recurrence: A multi-institutional observational study	Jae Hyun Yoon
P-134	TACE Alone vs Combination Therapies in Hepatocellular Carcinoma: A Pilot Study Based on Real Life Data in Unselected Patients	Cosmas Rinaldi Adithya Lesmana
P-135	UCHL1 Hijacks Tolerogenic Dendritic Cell Maturation and Promotes mregDC-Treg Crosstalk to Nullify Checkpoint Blockade	Yufei Zhao
P-136	Camrelizumab + Rivoceranib vs Sorafenib (CARES-310) as First-line Treatment for Patients with Unresectable Hepatocellular Carcinoma of Non-viral and Viral Etiology	Stephen L Chan
P-137	Targeted and Immune Checkpoint Inhibitor plus Hepatic Arterial Infusion Chemotherapy for Initially Diagnosed Unresectable Hepatocellular Carcinoma	Maopei Chen
P-138	Efficacy and safety of first-line atezolizumab plus bevacizumab versus lenvatinib plus pembrolizumab for unresectable hepatocellular carcinoma: a nationwide multicenter study	Chen-Ta Chi

P-139	Peripheral Blood Inflammatory Score Using a Cytokine Multiplex Assay Predicts Clinical Outcomes in Patients Treated with Atezolizumab-Bevacizumab for Unresectable HCC	Jong Young Choi
P-140	Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: Real-World Evidence from a Multicenter Study	Guohong Han
P-141	Quadruple Therapy (TACE-HAIC + TKIs + PD-1 Inhibitors) for Advanced HCC with Portal Vein Tumor Thrombus: Efficacy and Safety	Jianhua Huang
P-142	Subset of CPS 7 Shows Comparable Survival Outcomes to CPS 6 in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab	Jaejun Lee
P-143	Developing Novel Phytochemical-Derived Zingerone Nanoparticles as A Potent Chemopreventive Strategy for Human Hepatocellular Carcinoma	Mei-Lang Kung
P-144	Anti-angiogenic Adverse Events Predict for Improved Survival with Atezolizumab-Bevacizumab in Patients with Advanced Hepatocellular Carcinoma	Joycelyn J X Lee
P-145	Utility of Alpha-Fetoprotein and PIVKA-II kinetics as radiologic and survival outcomes in patients with unresectable hepatocellular carcinoma undergoing immunotherapy	Shou Wu Lee
P-146	CRAFITY-100 RULE score as a predictive factor of survival outcome in patients with unresectable hepatocellular carcinoma undergoing immunotherapy	Shou-Wu Lee
P-147	Development and Validation of a Risk Prediction Model for Patients with Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab	Sung Won Lee
P-148	Glycemic control determines the therapeutic responses to immunotherapy in diabetic patients with hepatocellular carcinoma	Meng-Wei Lin
P-149	Efficacy and Safety of TACE-HAIC-MTTs-ICIs vs. TACE-MTTs-ICIs in Hepatocellular Carcinoma: Prognostic Analysis of Serum AFP Dynamics	Wenli Li
P-150	Effectiveness and Safety of Atezolizumab Combined with Bevacizumab in Patients with Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam	Nguyen Thi Hoa
P-151	From Palliation to Cure: Curative Resection of Advanced HCC Achieved through Selective Internal Radiation Therapy Conversion	Zhihao Niu
P-152	Tremelimumab plus Durvalumab in Participants with Unresectable Hepatocellular Carcinoma (uHCC) from Mainland China in the Phase 3 HIMALAYA Study	Shukui Qin
P-153	Two complete-response cases to Lenvatinib for recurrence after radical hepatectomy against hepatocellular carcinoma with massive tumor thrombus.	Keiji Sano
P-154	Outcomes and Indications of Curative Conversion Therapy After Immunotherapy	Kentaro Tai
P-155	Efficacy and Safety of Atezolizumab Plus Bevacizumab in Elderly Patients with Unresectable Hepatocellular Carcinoma : A Single-Center Retrospective Analysis	Tomonao Taira
P-156	Differences in Regulatory Approvals and Guidelines for Durvalumab and Tremelimumab Combination Therapy and Durvalumab Monotherapy in Hepatocellular Carcinoma Across Countries	Hideaki Takahashi
P-157	The different of surgical treatment or transcatheter arterial chemoembolization combined with systemic treatment for spontaneously ruptured hepatocellular carcinoma	Kui Wang
P-158	A Real-World Study of Lenvatinib + PD-1 + GEMOX in the First-Line of Cholangiocarcinoma	Xiaozhun Huang
P-159	Impact of endoscopic retrograde cholangiopancreatography in hepatocellular carcinoma patients with bile duct invasion receiving atezolizumab plus bevacizumab	Hyun Young Woo
P-160	Bufalin Induces Immunogenic Cell Death and Synergizes with Doxorubicin to Suppress Hepatocellular Carcinoma	Zhuo Yu

P-161	Comparison of neoadjuvant therapy plus surgery, surgery alone, and surgery plus adjuvant therapy on prognosis in patients with hepatocellular carcinoma	Feng Zhang
P-162	Comparison of Treatment Efficacy and Safety Profile of Atezolizumab Plus Bevacizumab in BCLC B and C Patients with Hepatocellular Carcinoma	Jae Hyun Yoon
P-163	Metabolic Dysfunction-Associated Steatotic Liver Disease Increases Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Systematic Review and Meta-Analysis	Han Ah Lee
P-164	Long-Term Kidney Function in Chronic Hepatitis B Patients Treated with High Genetic Barrier Agents: Results from a Korean Nationwide Study	Jae Hyun Yoon
P-165	<i>Withdrawal</i>	
P-166	Effect of diabetes on the risk of fibrosis progression in patients with chronic hepatitis B	Mi Na Kim
P-167	Risk Factors for Hepatocellular Carcinoma After Sustained Virologic Response in Patients Treated with Glecaprevir/Pibrentasvir: A Prospective Cohort Study	Jung Hee Kim
P-168	Aspirin use and risk of HCC and gastrointestinal bleeding in patients with HBV-related cirrhosis: A landmark analysis	Mi Na Kim
P-169	Individual and combined CMRFs on liver-related outcomes in CHC patients with SLD after curative antiviral therapy	Ming-Lung Yu
P-170	Evaluation of Diep Ha Chau (DHC) Combined with Tenofovir Disoproxil Fumarate (TDF) in the Treatment of Chronic Hepatitis B	Tien K H
P-171	Efficacy of TACE based multimodal treatment in patients with neuroendocrine tumors involving the liver	Rongxin Chen
P-172	Radiotherapy for elderly patients with liver-confined hepatocellular carcinoma	Sun Hyun Bae
P-173	Combining Radiotherapy and Anti-CCR8 to Improve the Tumor Immune Microenvironment and Overcome Radioresistance in Liver Cancer	Huanliang Chen
P-174	Thermo Ablation is Reasonable for Singular Sub Centimeter Hepatocellular Carcinoma.	Maopei Chen
P-175	Retrospective Analysis of Molecular Subtype-Driven Precision Management in Intrahepatic Cholangiocarcinoma (Large-Duct vs. Small-Duct Types)	Yunfu Cui
P-176	Long-term overall survival after hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for unresectable hepatocellular carcinoma	Shiguang Chen
P-177	Current Status and Advances of Yttrium-90 Selective Internal Radiation Therapy for Hepatocellular Carcinoma at Tsinghua Changgung Hospital	Xiaobin Feng
P-178	Safety and Efficacy of Yttrium-90 Selective Internal Radiation Therapy for Massive Hepatocellular Carcinoma: A Single-Center Experience in China	Wuhua Guo
P-179	Efficacy and Safety of SIRT Combined with Low-dose HAIC, TKIs and ICIs for Unresectable Large HCC	MingZhi Hao
P-180	Refined conversion surgery treatment for liver cancer mediated by a ultra-stable lipiodol drug sustained release formula	Pan He
P-181	Feasibility Assessment of Novel Radiotherapy for Abdominal Cancer	Shih-Ming Hsu
P-182	SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Tumor Burden Hepatocellular Carcinoma: a Multicenter, Retrospective, Propensity Score-Matched Study	Jingjun Huang
P-183	Why does Combination Radiotherapy with Tyrosine Kinase Inhibitors Improve Survival of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis ?	Ling Hui Huang
P-184	Outcome of RFA for First Recurrence after Resection of Hepatocellular Carcinoma and Risk Factors for Recurrence after RFA	Go Igarashi
P-185	Comparing Clinically Significant Lung Shunt Fraction in Hepatocellular Carcinoma and Cholangiocarcinoma Yttrium-90 Mapping Procedures	Jonas Jaymes Kruse

P-186	Survival Outcomes of Transarterial Treatment versus Systemic Therapy as Initial Treatment for Hepatocellular Carcinoma with Extrahepatic Metastasis	Jaejun Lee
P-187	CD44 Promotes Radiation-Induced Liver Disease via Kupffer Cell M1 Polarization and the NF- κ B Signaling Pathway	Yanyan Lin
P-188	Efficacy and safety of SIRT combined with TACE or HAIC and systemic therapy for unresectable hepatocellular carcinoma: a case series	Hao Lu
P-189	Multi-dimensional analysis of yttrium-90 microsphere selective internal radiation therapy in liver tumors: tumor biological differences, treatment parameters, and short-term efficacy	Jingqin Ma
P-190	Case share of HAIC plus systemic therapy in unresectable HCC aimed for conversion	Sumou Ingrid Karmane
P-191	Yttrium-90 Selective Internal Radiation Therapy versus Stereotactic Body Radiation Therapy for Unresectable Hepatic Malignancies: A Retrospective Cohort Study	GuanWu Wang
P-192	On-Demand Locoregional Therapy Benefits Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Sorafenib or Lenvatinib Treatment	Hung-Wei Wang
P-193	Selective Internal Radiation Therapy Combined by Atezolizumab-Bevacizumab is a Promising Treatment for Unresectable Hepatocellular Carcinoma: A Chinese Clinical Experience	Leyang Xiang
P-194	Oleanolic acid sensitizes radiotherapy and prevents radiation-induced liver injury in hepatocellular carcinoma	Shuxuan Wang
P-195	Radioembolization with 90Y-microspheres Liver Cancer Treatment: Radioactive Hepatectomy and Efficacy Evaluation : A Case Series Analysis	Weizhi Xu
P-196	Efficacy and safety of yttrium-90 (SIRT) combined with HAIC and other therapeutic in the treatment of end-stage HCC	Shengli Ye
P-197	Surgical Resection Versus Stereotactic Body Radiation Therapy for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity-Weighted Analysis	Sang Min Yoon
P-198	Clinical Application of a Novel 0.035 inch Inner Diameter Microcatheter as an Intermediate Catheter in Selective Transcatheter Arterial Chemoembolization	Yuki Yoshino
P-199	Efficacy and Safety of SIRT in Patients with HCC as an Initial or Subsequent Treatment after Failure of Previous Treatment	Wenchang Yu
P-200	Safety and Efficacy of Yttrium-90 Selective Internal Radiation Therapy for Huge Hepatocellular Carcinoma (≥ 10 cm): a Case Series from China	Hongwei Zhang
P-201	Selective Internal Radiation Downstaging Strategy HCC Beyond Milan criteria: A Chinese Retrospective Study	Hui Zhang
P-202	Outcomes of Selective Internal Radiation Therapy with Yttrium-90 in Super-giant (≥ 15 cm) Hepatocellular Carcinoma: A Case Series	Jianwen Zhang
P-203	Efficacy of Radiation Therapy and Targeted Therapy Combined with or without Immunotherapy for Lymph Node Metastases in Hepatocellular Carcinoma	Li Zhang
P-204	Precision Medicine-Guided Radiation Segmentectomy Using Selective Internal Radiation Therapy: Efficacy and Safety in Hepatocellular Carcinoma Patients	Lin Zhang
P-205	Preoperative HAIC Enlarges Future Liver Remnant (FLR) in Initially Unresectable Hepatocellular Carcinoma Patients with Vp3 Tumor Thrombus	Yifan Zhang
P-206	Standard-of-care systemic therapy with or without radiotherapy in patients with unresectable intrahepatic cholangiocarcinoma	QianQian Zhao
P-207	[Late Breaking] A Structured Conversion Strategy Using RESECT-S to Identify Resectable Candidates Among Unresectable HCC Patients Receiving CAR-T Therapy	Yohan Lim
P-208	Liver Resection Combined With Microwave Ablation Versus Liver Resection Alone for Patients with Early and Intermediate Stage Multifocal Hepatocellular Carcinoma	Shenyu Zhang

ACKNOWLEDGMENT OF SPONSORS

The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2025) is grateful for the support of the following companies and organizations:

Abbvie GK

Astellas Pharma Inc.

AstraZeneca K.K.

Bristol-Myers Squibb

Canon Medical Systems

CHUGAI PHARMACEUTICAL CO., LTD.

Eisai Co., Ltd.

GE HealthCare

HistoSonics

miyano medical machine

Olympus Marketing, Inc.

ONO PHARMACEUTICAL CO., LTD.

Roche

Shanghai Xinxin Medical Science & Technology Development Foundation

The Federation of Pharmaceutical Manufacturers' Associations of JAPAN

KOBE TOURISM BUREAU • KOBE CONVENTION BUREAU

(As of July 01, 2025)



抗悪性腫瘍剤/ヒト型抗ヒトPD-L1モノクローナル抗体

薬価基準収載

イミフィンジ[®]点滴静注 120mg・500mg

IMFINZI[®] Injection 120mg・500mg デュルバルマブ(遺伝子組換え)製剤
生物由来製品/劇薬/処方箋医薬品(注意一医師等の処方箋により使用すること)
最適使用推進ガイドライン対象品目

抗悪性腫瘍剤/ヒト型抗ヒトCTLA-4モノクローナル抗体

薬価基準収載

イジユド[®]点滴静注 25mg・300mg

IMJUDO[®] Injection 25mg・300mg トレメリムマブ(遺伝子組換え)製剤
生物由来製品/劇薬/処方箋医薬品(注意一医師等の処方箋により使用すること)

「効能又は効果」、「用法及び用量」、「警告・禁忌を含む注意事項等
情報」等については製品電子添文をご参照ください。

製造販売元[文献請求先]

アストラゼネカ株式会社
大阪市北区大深町3番1号

TEL 0120-189-115

(問い合わせ先フリーダイヤル メディカルインフォメーションセンター)



健康と科学に奉仕する

宮野医療器株式会社



本社 〒650-8677 神戸市中央区楠町5丁目4-8
電話(078)371-2121(ダイヤルイン)
大倉山別館 〒650-8677 神戸市中央区楠町2丁目3-11
電話(078)371-2121(ダイヤルイン)
MSCコア75 〒651-2228 神戸市西区見津が丘4丁目11番5号プロロジスパーク神戸3
電話(078)995-3010(代表)
MSCポートアイランド60 〒650-0047 神戸市中央区港島南町4丁目6-1
電話(078)302-7001(代表)
MSCイースト70 〒596-0817 岸和田市岸の丘町2丁目2番10号
電話(072)447-6208(代表)
MSCウエスト 〒654-0161 神戸市須磨区弥栄台2丁目12-1
電話(078)797-2072(代表)
神戸中央営業所 〒650-0047 神戸市中央区港島南町4丁目6-1
電話(078)302-7001(代表)
神戸西営業所 〒654-0161 神戸市須磨区弥栄台2丁目12-1
電話(078)797-2072(代表)
姫路営業所 〒670-0940 姫路市三左衛門堀西の町7番地
電話(079)281-0880(代表)
明石営業所 〒674-0083 明石市魚住町住吉2丁目1-33
電話(078)947-3237(代表)
中兵庫営業所 〒669-3304 丹波市柏原町上小倉152-1
電話(0795)72-2288(代表)
北兵庫営業所 〒668-0063 豊岡市正法寺46-2
電話(0796)24-1170(代表)
阪神営業所 〒661-0026 尼崎市水堂町3丁目15-14
電話(06)6436-5678(代表)
大阪支社 〒564-0002 吹田市岸部中2丁目2-13
電話(06)6821-7171(代表)
大阪北営業所 〒564-0002 吹田市岸部中2丁目2-13
電話(06)6821-7111(代表)
大阪中央営業所 〒553-0006 大阪市福島区吉野5-5-8
電話(06)6468-3701(代表)
大阪東営業所 〒578-0948 東大阪市菱屋東2丁目14-20
電話(06)4308-6160(代表)
大阪南営業所 〒596-0817 岸和田市岸の丘町2丁目2番10号
電話(072)447-6208(代表)
和歌山営業所 〒640-8322 和歌山市秋月412番地の1
電話(073)475-2365(代表)
京都営業所 〒601-8188 京都市南区上鳥羽南中ノ坪町20番地
電話(075)692-3921(代表)
舞鶴出張所 〒624-0906 舞鶴市宇倉谷1555番地の4
電話(0773)78-2881(代表)
奈良営業所 〒639-1044 奈良県大和郡山小泉町東1丁目6-2
電話(0743)59-5151(代表)

岡山営業所 〒700-0945 岡山市南区新保1307番1
電話(086)805-0211(代表)
広島営業所 〒733-0842 広島市西区井口5丁目23-15
電話(082)270-0530(代表)
福山営業所 〒721-0973 福山市南蔵王町3丁目12-13
電話(084)973-1080(代表)
鳥取営業所 〒680-0902 鳥取市秋里1356番地
電話(0857)26-6771(代表)
米子営業所 〒689-3547 米子市流通町158-19
電話(0859)37-1610(代表)
高松営業所 〒761-0312 高松市東山崎町435-2-102
電話(087)847-3430(代表)
名古屋営業所 〒459-8001 名古屋市緑区大高町字坊主山1-12ESR内
電話(052)629-1260(代表)
三重出張所 〒510-0834 四日市市ときわ5丁目2番20号
電話(059)356-8174(代表)
東京営業所 〒113-0034 東京都文京区湯島2丁目16-7
電話(03)3816-4575(代表)
神奈川営業所 〒244-0815 横浜市戸塚区下倉田町828番地335
電話(045)869-5150(代表)
埼玉営業所 〒359-0021 所沢市東所沢2丁目54-12
電話(04)2945-2033(代表)
福岡営業所 〒811-1323 福岡市南区弥永5丁目26番3号
電話(092)571-2993(代表)
北九州営業所 〒802-0832 北九州市小倉南区下石田3丁目5番24号
電話(093)963-6161(代表)
熊本営業所 〒861-8035 熊本市東区御領6丁目3番34号
電話(096)389-8833(代表)

モイラン神戸店 〒650-8677 神戸市中央区楠町5丁目4-8
電話(078)371-2130(代表)
モイラン姫路店 〒670-0940 姫路市三左衛門堀西の町7
電話(079)283-2061(代表)
モイラン阪神店 〒661-0026 尼崎市水堂町3丁目15-14
電話(06)6434-5711(代表)
モイラン大阪店 〒553-0006 大阪市福島区吉野5丁目5-8
電話(06)6468-2220(代表)
モイラン鳥取店 〒680-0902 鳥取市秋里1356番地
電話(0857)26-6771(代表)



抗ウイルス化学療法剤

処方箋医薬品^(注) 薬価基準収載

マヴィレット[®] 配合錠

配合顆粒小児用



MAVIRET[®]

グレカプレビル水和物・ピブレンタスビル配合剤

(注) 注意—医師等の処方箋により使用すること

● 効能又は効果、用法及び用量、警告・禁忌を含む注意事項等情報等については電子化された添付文書(電子添文)をご参照ください。

製造販売元

アッヴィ合同会社

東京都港区芝浦3-1-21

2023年11月作成
JP-MAVI-220345-2.0

(文献請求先及び問い合わせ先)
くすり相談室
フリーダイヤル 0120-587-874

abbvie



Passionate about patient care

Eisai's passionate commitment to patient care is the driving force behind our efforts to find innovative solutions that help address unmet medical needs and contribute to the well-being of patients worldwide. With therapies in oncology and specialty care, we focus on having an impact on patients and their families. At Eisai, human health care is our goal.



h/c
human health care

CORP-US0023

©2017 Eisai Inc.

All rights reserved.

Aug 2017

www.eisai.com



We don't only fight disease.

We also take on drug discovery paradigms.

Our unprecedented medicines are
a step ahead of illness.

And when the world says there's no cure,
we don't give up until we find one.

INNOVATION BEYOND IMAGINATION



CHUGAI PHARMACEUTICAL CO., LTD.



Roche Group



HistoSonics Histotripsy System

Destroying and liquefying liver tumors noninvasively by leveraging histotripsy's non-thermal, non-ionizing, mechanical mechanism of action.

Minimally Invasive
isn't Minimal Enough

Learn more here:



Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. The HistoSonics Histotripsy System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the HistoSonics Histotripsy System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Not yet available for sale in Japan.

Today Astellas is working to meet
unmet medical needs.

All around the world there are diseases
for which no medicine has been developed.

Such unmet medical needs are the
battleground of Astellas.

Our mission is to change tomorrow
for millions of lives, one drug at a time.

www.astellas.com/en/

Changing tomorrow



Astellas Pharma Inc.

OLYMPUS

See clearly & Treat safely

**VISERA
ELITE III**



THUNDERBEAT

SONICBEAT

POWERSEAL

HICURA

オリンパスが追い続けるもの。

それは、最先端の技術を採用した内視鏡システムと幅広い手技に対応したエネルギーデバイスにより手技における「視認性」と「安全性」の向上を両立し、医療の発展に貢献することです。

製造販売元	オリンパスメディカルシステムズ株式会社
販売名	医療機器番号
VISERA ELITE II ヒダシステムセンター OLYMPUS OTV-S700	13B1X00277000699
パワーシール	30400BZX00265000
サージカル ディスクリュー マネージメント システム	22500BZX00335000
サンダービート タイプ S	22800BZX00417000
内視鏡外科手術用処置具 HICURA	13B1X00277000552

オリンパス マーケティング株式会社

www.olympus.co.jp

R900U

Creating a world where
healthcare has no limits



GE HealthCare

GEヘルスケア・ジャパン株式会社

カスタマー・コールセンター 0120-202-021

【受付時間】 9:00~18:00 ※土・日・祝を除く

gehealthcare.com

JB09455JA



APPLE 2026

The 16th Asia-Pacific PrimaryLiver Cancer Expert Meeting

July 7.2026 Shanghai·China





Our passion ignites progress

At Eisai, *human health care* is our goal. We give our first thoughts to patients and their families as well as helping to increase the benefits health care provides. Our therapies and diverse pipeline are designed to make a difference and have an impact on patients' lives. We are Eisai, where medicine is more than just our business — it's our passion.



hhe
human health care